Workflow
港股通
icon
Search documents
嘉实恒指港股通交易型开放式指数证券投资基金基金份额发售公告
Group 1 - The fund is named "Jia Shi Hangzhi Hong Kong Stock Connect Exchange-Traded Open-Ended Index Securities Investment Fund" and is registered with the China Securities Regulatory Commission [1][11] - The fund is an equity index fund that operates as an exchange-traded fund (ETF) [11] - The fund's target index is the Hang Seng Index Hong Kong Stock Connect Index, which reflects the performance of the constituent stocks that can be traded through the Hong Kong Stock Connect [9][11] Group 2 - The public offering period for the fund is from October 9, 2025, to October 17, 2025, with options for online and offline cash subscriptions [2][14] - The fund does not have a cap on the total amount raised [10][12] - Subscription fees for the fund will not exceed 0.80% of the subscription amount [8][17] Group 3 - Investors must have a Shanghai Stock Exchange A-share account or a securities investment fund account to subscribe to the fund [7][22] - The minimum subscription amount for online cash subscriptions is 1,000 shares or multiples thereof, while offline cash subscriptions require a minimum of 5,000 shares [21][32] - The fund's management company is Jia Shi Fund Management Co., Ltd., and the custodian is Guojin Securities Co., Ltd. [1][42]
港股通数据统计周报 2025.9.15-2025.9.21-20250923
Group 1: Top Net Buy/Sell Companies - Alibaba-W (9988.HK) had the highest net buy amount of ¥22.247 billion with a holding change of 139,830,551 shares[8] - BeiGene (6160.HK) ranked second with a net buy of ¥2.019 billion and a holding change of 10,056,137 shares[8] - Xiaomi Group-W (1810.HK) was the top net sell company with a net sell amount of -¥1.948 billion and a holding change of -34,353,051 shares[9] Group 2: Industry Distribution - The financial sector saw a net buy of ¥1.630 billion, primarily driven by China Pacific Insurance (2601.HK) and Industrial and Commercial Bank of China (1398.HK)[8][9] - The healthcare industry had a total net buy of ¥3.046 billion, with significant contributions from BeiGene (6160.HK) and Innovent Biologics (9606.HK)[8][9] - The technology sector experienced a net sell of -¥12.94 billion, largely due to Tencent Holdings (0700.HK) and Xiaomi Group-W (1810.HK)[9] Group 3: Active Stocks - Alibaba-W (9988.HK) was the most active stock with a total trading volume of ¥70.25 billion and a net buy of ¥4.73 billion on the Shanghai Stock Connect[18] - Semiconductor Manufacturing International Corporation (0981.HK) had a trading volume of ¥62.79 billion with a net sell of -¥3.08 billion on the Shenzhen Stock Connect[18] - Meituan-W (3690.HK) recorded a trading volume of ¥44.40 billion with a net buy of ¥5.68 billion on the Shanghai Stock Connect[19]
深交所:深港通下的港股通标的证券名单调整 调入晋景新能
Group 1 - The Shenzhen Stock Exchange announced an adjustment to the list of Hong Kong Stock Connect eligible securities due to the share split of Jin Jing New Energy (01783) [1] - The adjustment will take effect from September 23, 2025, with Jin Jing New Energy (02945) being added to the list [1]
智通港股通活跃成交|9月19日
智通财经网· 2025-09-19 11:02
Core Insights - On September 19, 2025, Alibaba-W (09988), SMIC (00981), and Shankai Holdings (00412) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 70.25 billion, 62.79 billion, and 38.99 billion respectively [1] - In the Southbound Stock Connect for the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), SMIC (00981), and Tencent Holdings (00700) also ranked as the top three, with trading amounts of 45.57 billion, 33.96 billion, and 15.89 billion respectively [1] Southbound Stock Connect (Hong Kong-Shanghai) - The top three active companies by trading volume were: - Alibaba-W (09988): 70.25 billion with a net buy of +4.73 billion - SMIC (00981): 62.79 billion with a net buy of +3.08 billion - Shankai Holdings (00412): 38.99 billion with a net buy of +17.21 billion [2] - Other notable companies included: - Changfei Optical Fiber (06869): 24.82 billion with a net sell of -69.08 million - Pop Mart (09992): 24.49 billion with a net buy of +9.01 billion [2] Southbound Stock Connect (Shenzhen-Hong Kong) - The top three active companies by trading volume were: - Alibaba-W (09988): 45.57 billion with a net buy of +12.54 billion - SMIC (00981): 33.96 billion with a net sell of -2.15 billion - Tencent Holdings (00700): 15.89 billion with a net buy of +27.91 million [2] - Other notable companies included: - Xiaomi Group-W (01810): 15.49 billion with a net sell of -43.27 million - Innovent Biologics (01801): 15.23 billion with a net sell of -37.09 million [2]
突然,“入通”股频频巨震,发生了什么?
Zheng Quan Shi Bao· 2025-09-18 14:57
近日,多只港股被纳入港股通标的后,股价暴涨暴跌,波动大幅加剧。 对于出现此种现象的原因,市场认为有多种可能,包括指数成份股调整导致相关ETF被动买入、新晋港 股通标的身份带来南向港股通资金"活水"买盘、市场投机资金借概念炒作,以及部分新晋港股通标的上 市时间不久,导致实际流通交易的股份数相对较少等。 值得注意的是,从现有案例来看,港股被纳入港股通标的可能给相关股票带来投资机会,但市场狂热后 也往往导致价格阶段性虚高,造成投资风险。 多只港股"入通"后剧烈波动 日前,港股通标的证券名单调整并自2025年9月8日起生效,其中20只证券被纳入。多只股票"入通"后涨 势加速,波动明显加大。 炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 最为典型的是药捷安康-B。数据显示,药捷安康-B在被纳入港股通标的后股价即加速上涨,9月8日当天 大涨20.13%,在短短几个交易日里最高涨幅逾10倍。但自9月16日开始,药捷安康-B股价开始剧烈调 整,当天大跌53.73%。9月18日,药捷安康-B再跌12.43%。 佰泽医疗在被纳入港股通标的后,波动幅度也明显加大,其中9月12日盘中一度大涨逾27%,全天 ...
港股异动 | 正力新能(03677)盘中飙升逾14% 公司近期进入港股通名单 规模效应和高产能利用率有望持续
Zhi Tong Cai Jing· 2025-09-18 03:20
智通财经APP获悉,正力新能(03677)盘中飙升逾14%,截至发稿,涨5.67%,报11.92港元,成交额2.13 亿港元。 消息面上,正力新能此前公布,公司股份已被调入沪港通及深港通下港股通标的证券名单,自9月8日起 生效。董事会认为,公司被调入沪港通及深港通下港股通标的证券名单,将有助加快扩大公司股东基础 及提高公司股份的交易流通性,并进一步提高公司在资本市场上的声誉及公司的品牌知名度。 招银国际发布研报称,作为后起之秀,正力新能的历史包袱远轻于多数同业,叠加管理层通过标准化电 芯和平台化电池包提升制造效率的战略,构成公司核心竞争优势。该行指出,正力在客户集中度较高的 情况下就实现了最近两个报告期的盈利并实现了行业领先的毛利率,主要原因可归结为高产能利用率、 先进制造产线和卓越管理能力;从客户结构看,规模效应和高产能利用率将至少持续至2026年末,而客 户的结构改善或进一步提升利润率:预计广汽丰田将在今年成为正力的第二大客户,而随着为大众增程 车型的配套,预计外资品牌将在2027年贡献正力约一半的收入。 ...
药捷安康:2小时市值蒸发近2000亿!一场没有产品的资本狂欢,是谁在收割?
Sou Hu Cai Jing· 2025-09-17 09:45
更让人惊讶的是,这家2014年成立、专注抗癌和代谢病创新药的公司,至今没有一个产品上市!没错, 没有产品收入!去年还亏损了2.75亿,今年上半年又亏了1.23亿。 就这基本面,股价却从9月开始突然起飞——原因很简单:它被纳入港股通名单,还拿到了核心产品 的"临床默示许可",可以开始二期试验了。 2小时市值蒸发了1900多亿港元?一家没有产品上市的公司,竟能拥有2700亿港元的市值? 1934亿港元的市值蒸发需要多久?药捷安康告诉你:只要2小时! 这一切始于9月16日上午,药捷安康的股价一路狂飙,创下历史新高,市值逼近2700亿港元!什么概 念?相当于"康方生物+药明生物"两家医药巨头加起来的总和!就问你牛不牛?是不是感觉财富自由在 招手? 但荒诞的来了!下午2点之后,剧情突然反转,股价从每股600多港元,像自由落体一样,跌破200港 元!短短两个多小时,市值蒸发近2000亿港元!股价全天跌了53.73%,如果从最高点算更是暴跌70%。 这走势,就问你刺不刺激? 盘子小,股价更是容易被快速拉升,叠加两则利好消息,市场资金迅速涌入,股价一路狂奔。 但你说光靠一个许可,就能撑起2700亿港元的市值?这下可苦了那些跟 ...
BOSS直聘公开发售破局流动性 港股成交额虽翻28倍 但入港股通日均成交额需稳超5300万港元
Xin Lang Zheng Quan· 2025-09-17 03:57
Core Viewpoint - The liquidity of Chinese concept stocks returning to Hong Kong has shown significant differentiation, with larger companies facing liquidity challenges despite their market capitalization [1][2]. Group 1: Liquidity Challenges - As of mid-2025, among 31 Chinese concept stocks returning to Hong Kong, 12 have been included in the Hong Kong Stock Connect, leading to a more balanced trading level between US and Hong Kong stocks [1]. - BOSS Zhipin, despite a market capitalization of nearly 65 billion HKD, has faced persistent liquidity issues since its introduction to the Hong Kong market in December 2022 without raising funds [2][3]. - The average daily trading volume for BOSS Zhipin in Hong Kong was only 1.24 million HKD, with a turnover rate of 0.002%, compared to 5.6 billion HKD in the US market, highlighting a stark contrast in trading activity [2]. Group 2: Public Offering to Improve Liquidity - To address its liquidity issues, BOSS Zhipin launched a public offering on June 25, 2025, issuing 34.5 million shares at a price of 66.0 HKD per share, raising a net amount of 2.2 billion HKD [3][4]. - The public offering allowed participation from retail investors, which is expected to enhance liquidity by diversifying the shareholder base and increasing daily trading activity [3][4]. - Following the public offering, BOSS Zhipin's average daily trading volume surged to 35.2 million HKD, an increase of approximately 28.4 times, and the turnover rate rose to 0.05%, a 23.7-fold increase [5][6]. Group 3: Challenges in Meeting Stock Connect Requirements - Despite improvements in liquidity, BOSS Zhipin faces challenges in meeting the Stock Connect eligibility criteria, which require an average market capitalization of at least 20 billion HKD and total trading volume of 6 billion HKD over 183 trading days [6][7]. - As of September 16, 2025, BOSS Zhipin had only achieved 31% of the required total trading volume, indicating significant hurdles in reaching the necessary thresholds for inclusion in the Stock Connect [6][7]. Group 4: Executive Selling and Market Sentiment - Following the public offering, BOSS Zhipin's CTO sold shares in the US market, raising concerns about potential negative market sentiment among retail investors [7][9]. - The executive's selling activity could be interpreted as a cautious signal regarding the company's short-term outlook, which may affect trading enthusiasm among newly attracted retail investors [9]. - The company needs to maintain market confidence through positive operational disclosures and effective shareholder communication to balance shareholder returns and market stability [9].
50倍大妖股!惊魂过山车!
Ge Long Hui· 2025-09-16 12:08
药捷安康成为最近港股备受瞩目的焦点。 近一周的暴涨的背后,到底是行情驱动,还是精心操纵? 01 在部分人看来,药捷安康这波行情,并非无的放矢。 今年以来,整个创新药板块均表现不错。截止8月底,港股整个医药板块翻倍股达到16只,板块整体热度较高。 在上周市场纷纷讨论,药捷安康是否配得上其700亿市值之时,昨日,药捷安康股价再次暴涨,市值直接突破2500亿港元,超越康方生物等一众成熟药企。 今日盘中,药捷安康股价更是高见679.5港元,9月以来最大涨幅超10倍。 若从今年6月港股上市时,仅13.15港元/股的发行价算起,不到三个月的时间,药捷安康股价直接暴涨近50倍! 然而午后,药捷安康突发跳水,较日内高点跌超70%,总市值直接蒸发近2000亿港元。 来源:图虫 而在9月10日,药捷安康发布一则公告,披露其核心产品替恩戈替尼的一项II期临床试验获得了中国药监局的临床默示许可,被视为此次行情的主要推动力 之一。 公开资料显示,替恩戈替尼(Tinengotinib)是一款创新多靶点小分子激酶抑制剂(MKT),靶向FGFR/VEGFR、JAK和Aurora三大通路,通过靶向肿瘤细 胞和改善肿瘤微环境发挥抗肿瘤作用。 目 ...
50倍大妖股,惊魂过山车
Ge Long Hui· 2025-09-16 12:00
药捷安康成为最近港股备受瞩目的焦点。 在上周市场纷纷讨论,药捷安康是否配得上其700亿市值之时,昨日,药捷安康股价再次暴涨,市值直接突破2500亿港元,超越康方生物等一众成熟药 企。 今日盘中,药捷安康股价更是高见679.5港元,9月以来最大涨幅超10倍。 若从今年6月港股上市时,仅13.15港元/股的发行价算起,不到三个月的时间,药捷安康股价直接暴涨近50倍! 然而午后,药捷安康突发跳水,较日内高点跌超70%,总市值直接蒸发近2000亿港元。 近一周的暴涨的背后,到底是行情驱动,还是精心操纵? 01 在部分人看来,药捷安康这波行情,并非无的放矢。 今年以来,整个创新药板块均表现不错。截止8月底,港股整个医药板块翻倍股达到16只,板块整体热度较高。 而在9月10日,药捷安康发布一则公告,披露其核心产品替恩戈替尼的一项II期临床试验获得了中国药监局的临床默示许可,被视为此次行情的主要推动 力之一。 也是因此,替恩戈替尼可以说是药捷安康最具价值的核心资产之一,且除了替恩戈替尼,药捷安康的其他管线,都还处于相对早期的研发阶段,关注度也 不如替恩戈替尼。 也是因此,目前药捷安康还没有商业化产品,业绩也仍处于亏损状态。 ...